Stay updated on ABBV-105/Upadacitinib Combo Follow-Up Clinical Trial

Sign up to get notified when there's something new on the ABBV-105/Upadacitinib Combo Follow-Up Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the ABBV-105/Upadacitinib Combo Follow-Up Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-13T21:36:18.000Z thumbnail image
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a modification in the dosage or quantity of a specific drug or treatment related to rheumatoid arthritis in a clinical trial study.
    Difference
    0.1%
    Check dated 2024-06-06T14:31:53.000Z thumbnail image
  7. Check
    25 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for participants, specifying that researchers look for individuals who meet certain health conditions or have undergone prior treatments. The new criteria also mention that participants must have completed Study M16-063 and not developed any discontinuation criteria as defined in that study's protocol.
    Difference
    10%
    Check dated 2024-05-22T20:57:14.000Z thumbnail image
  8. Check
    46 days ago
    Change Detected
    Difference
    1%
    Check dated 2024-04-30T22:26:25.000Z thumbnail image

Stay in the know with updates to ABBV-105/Upadacitinib Combo Follow-Up Clinical Trial

Enter your email address, and we'll notify you when there's something new on the ABBV-105/Upadacitinib Combo Follow-Up Clinical Trial page.